FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158086853> ?p ?o ?g. }

• W2158086853 endingPage "889" @default.
• W2158086853 startingPage "889" @default.
• W2158086853 abstract "To investigate the effect of mesalazine granules on small intestinal injury induced by naproxen using capsule endoscopy (CE).This was a single center, non-randomized, open-label, uncontrolled pilot study, using the PillCam SB CE system with RAPID 5 software. The Lewis Index Score (LIS) for small bowel injury was investigated to evaluate the severity of mucosal injury. Arthropathy patients with at least one month history of daily naproxen use of 1000 mg and proton pump inhibitor co-therapy were screened. Patients with a minimum LIS of 135 were eligible to enter the 4-wk treatment phase of the study. During this treatment period, 3 × 1000 mg/d mesalazine granules were added to ongoing therapies of 1000 mg/d naproxen and 20 mg/d omeprazole. At the end of the 4-wk combined treatment period, a second small bowel CE was performed to re-evaluate the enteropathy according to the LIS results. The primary objective of this study was to assess the mucosal changes after 4 wk of mesalazine treatment.A total of 18 patients (16 females), ranging in age from 46 to 78 years (mean age 60.3 years) were screened, all had been taking 1000 mg/d naproxen for at least one month. Eight patients were excluded from the mesalazine therapeutic phase of the study for the following reasons: the screening CE showed normal small bowel mucosa or only insignificant damages (LIS < 135) in five patients, the screening esophagogastroduodenoscopy revealed gastric ulcer in one patient, capsule technical failure and incomplete CE due to poor small bowel cleanliness in two patients. Ten patients (9 female, mean age 56.2 years) whose initial LIS reached mild and moderate-to-severe enteropathy grades (between 135 and 790 and ≥ 790) entered the 4-wk therapeutic phase and a repeat CE was performed. When comparing the change in LIS from baseline to end of treatment in all patients, a marked decrease was seen (mean LIS: 1236.4 ± 821.9 vs 925.2 ± 543.4, P = 0.271). Moreover, a significant difference between pre- and post-treatment mean total LIS was detected in 7 patients who had moderate-to-severe enteropathy gradings at the inclusion CE (mean LIS: 1615 ± 672 vs 1064 ± 424, P = 0.033).According to the small bowel CE evaluation mesalazine granules significantly attenuated mucosal injuries in patients with moderate-to-severe enteropathies induced by naproxen." @default.
• W2158086853 created "2016-06-24" @default.
• W2158086853 creator A5024795186 @default.
• W2158086853 creator A5044560140 @default.
• W2158086853 creator A5045766707 @default.
• W2158086853 creator A5047321978 @default.
• W2158086853 creator A5063916904 @default.
• W2158086853 creator A5076712455 @default.
• W2158086853 date "2013-01-01" @default.
• W2158086853 modified "2023-10-18" @default.
• W2158086853 title "Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy" @default.
• W2158086853 cites W126275272 @default.
• W2158086853 cites W1569709067 @default.
• W2158086853 cites W1604674907 @default.
• W2158086853 cites W1650175677 @default.
• W2158086853 cites W1840927757 @default.
• W2158086853 cites W1926898034 @default.
• W2158086853 cites W1986775845 @default.
• W2158086853 cites W1987561135 @default.
• W2158086853 cites W1993846227 @default.
• W2158086853 cites W2004295101 @default.
• W2158086853 cites W2008030932 @default.
• W2158086853 cites W2011683578 @default.
• W2158086853 cites W2013558239 @default.
• W2158086853 cites W2026939860 @default.
• W2158086853 cites W2027461487 @default.
• W2158086853 cites W2028605375 @default.
• W2158086853 cites W2039784446 @default.
• W2158086853 cites W2044292672 @default.
• W2158086853 cites W2044457654 @default.
• W2158086853 cites W2045116430 @default.
• W2158086853 cites W2048326934 @default.
• W2158086853 cites W2048567767 @default.
• W2158086853 cites W2052947072 @default.
• W2158086853 cites W2054305086 @default.
• W2158086853 cites W2059218639 @default.
• W2158086853 cites W2069447748 @default.
• W2158086853 cites W2075640920 @default.
• W2158086853 cites W2076476900 @default.
• W2158086853 cites W2079851763 @default.
• W2158086853 cites W2092237979 @default.
• W2158086853 cites W2098280618 @default.
• W2158086853 cites W2104628930 @default.
• W2158086853 cites W2107510055 @default.
• W2158086853 cites W2122355853 @default.
• W2158086853 cites W2138698403 @default.
• W2158086853 cites W2155979210 @default.
• W2158086853 cites W2163549160 @default.
• W2158086853 doi "https://doi.org/10.3748/wjg.v19.i6.889" @default.
• W2158086853 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3574886" @default.
• W2158086853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23431027" @default.
• W2158086853 hasPublicationYear "2013" @default.
• W2158086853 type Work @default.
• W2158086853 sameAs 2158086853 @default.
• W2158086853 citedByCount "12" @default.
• W2158086853 countsByYear W21580868532013 @default.
• W2158086853 countsByYear W21580868532014 @default.
• W2158086853 countsByYear W21580868532015 @default.
• W2158086853 countsByYear W21580868532016 @default.
• W2158086853 countsByYear W21580868532017 @default.
• W2158086853 countsByYear W21580868532019 @default.
• W2158086853 countsByYear W21580868532020 @default.
• W2158086853 countsByYear W21580868532021 @default.
• W2158086853 countsByYear W21580868532022 @default.
• W2158086853 countsByYear W21580868532023 @default.
• W2158086853 crossrefType "journal-article" @default.
• W2158086853 hasAuthorship W2158086853A5024795186 @default.
• W2158086853 hasAuthorship W2158086853A5044560140 @default.
• W2158086853 hasAuthorship W2158086853A5045766707 @default.
• W2158086853 hasAuthorship W2158086853A5047321978 @default.
• W2158086853 hasAuthorship W2158086853A5063916904 @default.
• W2158086853 hasAuthorship W2158086853A5076712455 @default.
• W2158086853 hasBestOaLocation W21580868531 @default.
• W2158086853 hasConcept C126322002 @default.
• W2158086853 hasConcept C142724271 @default.
• W2158086853 hasConcept C204787440 @default.
• W2158086853 hasConcept C2777333622 @default.
• W2158086853 hasConcept C2777498785 @default.
• W2158086853 hasConcept C2778115740 @default.
• W2158086853 hasConcept C2778426112 @default.
• W2158086853 hasConcept C2778451229 @default.
• W2158086853 hasConcept C2778778583 @default.
• W2158086853 hasConcept C2779134260 @default.
• W2158086853 hasConcept C2779174533 @default.
• W2158086853 hasConcept C2780479503 @default.
• W2158086853 hasConcept C2781143854 @default.
• W2158086853 hasConcept C59822182 @default.
• W2158086853 hasConcept C71924100 @default.
• W2158086853 hasConcept C86803240 @default.
• W2158086853 hasConcept C90924648 @default.
• W2158086853 hasConceptScore W2158086853C126322002 @default.
• W2158086853 hasConceptScore W2158086853C142724271 @default.
• W2158086853 hasConceptScore W2158086853C204787440 @default.
• W2158086853 hasConceptScore W2158086853C2777333622 @default.
• W2158086853 hasConceptScore W2158086853C2777498785 @default.
• W2158086853 hasConceptScore W2158086853C2778115740 @default.
• W2158086853 hasConceptScore W2158086853C2778426112 @default.
• W2158086853 hasConceptScore W2158086853C2778451229 @default.

• next